Related Experiment Videos
Congenital muscular dystrophy in Israeli families
Marianna Rachmiel1, Yoram Nevo, Eli Lahat
1Pediatric Neurology Unit, Asaf Harofe Medical Center, Zerifin, Israel.
Insights
Congenital muscular dystrophy (CMD) presents diverse clinical outcomes. Merosin-negative CMD often involves cognitive impairment, while merosin-positive CMD can lead to severe early-onset weakness and mortality.
Area of Science:
- Neurology
- Genetics
- Pediatrics
Background:
- Congenital muscular dystrophy (CMD) is a group of inherited disorders characterized by muscle weakness present at birth.
- Merosin (LAMA2) deficiency is a common subtype of CMD, but clinical presentations can vary significantly.
- Understanding the spectrum of clinical manifestations is crucial for diagnosis and management.
Purpose of the Study:
- To evaluate the clinical spectrum of congenital muscular dystrophy in Israeli families.
- To differentiate outcomes based on merosin status (negative vs. positive).
- To correlate clinical findings with serum creatine kinase levels and cognitive development.
Main Methods:
- Retrospective evaluation of twelve patients from eleven Israeli families diagnosed with CMD between 1991 and 2001.
- Classification of patients into merosin-negative and merosin-positive groups.
- Assessment of clinical features, including ambulation, cognitive function, and serum creatine kinase levels.
Main Results:
- Six patients were merosin-negative and six were merosin-positive.
- Merosin-negative patients exhibited highly elevated serum creatine kinase; two had cognitive impairment.
- Merosin-positive patients showed varied outcomes: four had severe early-onset weakness, ventilatory insufficiency, and died in infancy; two were ambulant with normal cognition and elevated creatine kinase.
Conclusions:
- Congenital muscular dystrophy exhibits diverse clinical phenotypes, influenced by merosin status.
- Merosin-negative CMD is associated with cognitive impairment in a subset of patients.
- Merosin-positive CMD can present with severe, fatal infantile forms, highlighting the importance of early diagnosis and supportive care.
Abstract:
Twelve patients from 11 Israeli families with congenital muscular dystrophy were evaluated between 1991 and 2001. There were six males and six females, of whom six were merosin negative and six were merosin positive. Serum creatine kinase levels were highly elevated in the merosin-negative group. Four of the children were cognitively normal but nonambulant. Two had unusual clinical findings of severe cognitive and motor developmental dysfunction. Four infants in the merosin-positive group who had normal serum creatine kinase levels had early-onset severe motor weakness and died within the first year of life owing to ventilatory insufficiency. The other two were ambulant and had normal cognitive development and elevated serum creatine kinase levels. Noteworthy, two of the six children with merosin-negative congenital muscular dystrophy had cognitive impairment, and four of the six children with merosin-positive congenital muscular dystrophy had a severe form of the disease with ventilatory insufficiency and death during infancy.